



European Medicines Agency

London, 18 March 2005
Doc. Ref. EMEA/18153/2005 Final

Comments Received on
EMEA/CHMP Working Group with Patients Organisations
“Recommendations and Proposals for Action”
(EMEA/CHMP/5819/04/Final)

(incl. abbreviations as used within the document containing all comments)

- | | |
|--|---|
| EU Commission | <ul style="list-style-type: none">- DG Enterprise- DG SANCO |
| National Competent Authorities | <ul style="list-style-type: none">- Dutch Medicines Evaluation Board (MEB)- Finnish National Agency for Medicines- German Ministry of Health and Social Security- Icelandic Medicines Control Agency- Norwegian Medicines Agency- Ministry of Health of the Czech Republic |
| Patient and Consumers Organisations | <ul style="list-style-type: none">- European Cancer Patient Coalition (ECPC)- European Organisation for Rare Diseases (Eurordis)- European Plasma Fractionation Association (EPFA) |
| Health Professionals | <ul style="list-style-type: none">- Standing Committee of European Doctors (CPME) |
| Industry | <ul style="list-style-type: none">- European Federation of Pharmaceutical Industries and Associations (EFPIA)- European Generic Medicines Association (EGA)- Merck Sharpe & Dohme (MSD) |
| Others | <ul style="list-style-type: none">- La Revue Prescrire- The Medicines Labelling Group (MLG) |